降压治疗预防房颤患者心血管事件的个体参与者数据荟萃分析
该研究基于BPLTTC个体参与者数据,纳入22项试验共188,570例患者,其中13,266例(7%)基线有房颤。中位随访4.5年,收缩压降低5 mmHg时,房颤患者主要心血管事件风险HR为0.91(95%CI 0.83-1.00),无房颤者为0.91(95%CI 0.88-0.93),亚组间无差异。结论认为降压治疗对房颤与无房颤患者的心血管获益相似,房颤患者应推荐药物降压以预防心血管事件。
要点
- 房颤患者收缩压降低5 mmHg可降低主要心血管事件风险,HR 0.91(95%CI 0.83-1.00)。
- 降压治疗在房颤与无房颤患者中的相对获益无显著差异。
- 房颤患者应推荐药物降压以预防心血管事件。
核心结论
- 降压治疗可相似地降低房颤与无房颤患者的主要心血管事件风险。
- 房颤患者应推荐药物降压以预防心血管事件。
研究设计与样本
- 基于BPLTTC个体参与者数据,纳入22项试验共188,570例患者,其中13,266例(7%)基线有房颤。
- 采用固定效应一阶段IPD荟萃分析,基于按试验分层的Cox比例风险模型估计降压治疗对主要心血管事件复合终点(卒中、缺血性心脏病或心力衰竭)的效果。
- 使用元回归评估降压强度与心血管结局的关联在房颤与无房颤患者中是否相似。
主要发现
- 中位随访4.5年,收缩压降低5 mmHg时,房颤患者主要心血管事件HR为0.91(95%CI 0.83-1.00),无房颤者为0.91(95%CI 0.88-0.93),亚组间无差异。
- 元回归显示,相对风险降低与试验水平降压强度成比例,在房颤与无房颤患者中均如此。
- 在房颤患者中,未发现按基线收缩压或药物类别存在治疗效应异质性的证据。
关键数值与推荐
- 共纳入22项试验,188,570例患者,其中13,266例(7%)基线有房颤。
- 偏倚风险评估显示20项试验为低风险,2项为中等风险。
- 收缩压降低5 mmHg时,房颤患者主要心血管事件HR 0.91(95%CI 0.83-1.00),无房颤者HR 0.91(95%CI 0.88-0.93)。
临床怎么用
- 对房颤患者应考虑药物降压以预防主要心血管事件。
- 降压获益与无房颤患者相似,支持在房颤患者中实施降压治疗。
局限性
- 试验数量有限。
- 因心律失常性质及房颤患者血压测量的限制,房颤病例的确认存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomised evidence on the efficacy of blood pressure (BP)-lowering treatment to reduce cardiovascular risk in patients with atrial fibrillation (AF) is limited. Therefore, this study aimed to compare the effects of BP-lowering drugs in patients with and without AF at baseline. METHODS AND FINDINGS: The study was based on the resource provided by the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC), in which individual participant data (IPD) were extracted from trials with over 1,000 patient-years of follow-up in each arm, and that had randomly assigned patients to different classes of BP-lowering drugs, BP-lowering drugs versus placebo, or more versus less intensive BP-lowering regimens. For this study, only trials that had collected information on AF status at baseline were included. The effects of BP-lowering treatment on a composite endpoint of major cardiovascular events (stroke, ischaemic heart disease or heart failure) according to AF status at baseline were estimated using fixed-effect one-stage IPD meta-analyses based on Cox proportional hazards models stratified by trial. Furthermore, to assess whether the associations between the intensity of BP reduction and cardiovascular outcomes are similar in those with and without AF at baseline, we used a meta-regression. From the full BPLTTC database, 28 trials (145,653 participants) were excluded because AF status at baseline was uncertain or unavailable. A total of 22 trials were included with 188,570 patients, of whom 13,266 (7%) had AF at baseline. Risk of bias assessment showed that 20 trials were at low risk of bias and 2 trials at moderate risk. Meta-regression showed that relative risk reductions were proportional to trial-level intensity of BP lowering in patients with and without AF at baseline. Over 4.5 years of median follow-up, a 5-mm Hg systolic BP (SBP) reduction lowered the risk of major cardiovascular events both in patients with AF (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.83 to 1.00) and in patients without AF at baseline (HR 0.91, 95% CI 0.88 to 0.93), with no difference between subgroups. There was no evidence for heterogeneity of treatment effects by baseline SBP or drug class in patients with AF at baseline. The findings of this study need to be interpreted in light of its potential limitations, such as the limited number of trials, limitation in ascertaining AF cases due to the nature of the arrhythmia and measuring BP in patients with AF. CONCLUSIONS: In this meta-analysis, we found that BP-lowering treatment reduces the risk of major cardiovascular events similarly in individuals with and without AF. Pharmacological BP lowering for prevention of cardiovascular events should be recommended in patients with AF.
引用
- Pinho-Gomes AC, Azevedo L, Copland E, et al. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. PLoS Med. 2021. PMID: 34061831. doi:10.1371/journal.pmed.1003599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。